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ДИРЕКТНИ ОРАЛНИ АНТИКОАГУЛАНСИ - БАЛАНС 
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Крвавењето е чест несакан ефект од употребата на антиокоагулантни лекови. Повеќето од крвавечки-
те компликации не се животозагрозувачки и можат да се третираат конзервативно. Прв чекор во ре-
шавање на значајно крвавење е привремено да се прекине антикоагулансот. Целта на овој труд беше 
да се одреди соодветната стратегија за акутно крвавење на пациент на ДОАК. Директните орални 
антиокоагуланси (ДОАК) се нашироко употребувани во третманот на венски тромбоемболизам (ВТЕ) 
и се препорачани како прва линија пред витамин К антагонисти (ВКА) кај ВТЕ која не е асоцирана со 
канцер. До скоро, супортивна терапија и инфузија на фактори на коагулација беа единствените дос-
тапни опции за пресврт на дејството на  ДОАК. Во последните 4 години одобрувањето на специфични 
антидоти ја зголемија надежта за подобар исход на крвавењата асоцирани со употреба на ДОАК, но сè 
уште постојат ограничувања како што се цената, достапноста и податоци од клиничката пракса. При 
тешки, животозагрозувачки крвавења, се препорачува употреба на неспецифични (пр. PCC) и специ-
фични (idarucizumab, andexanet alpha) агенси. Но, потребни се понатамошни искуства и податоци за 
споредба на исходот помеѓу двете стратегии во однос на бенефитот и економичноста.
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Bleeding is a common side effect of anticoagulant use. However, the majority of bleeding events 
are not life-threatening and can be managed conservatively. The first step in managing any 
significant bleeding event is to temporarily stop using the anticoagulant. The aim of this review 
was to determine the appropriate management strategy for an acutely bleeding patient on DOACs. 
Direct oral anticoagulants (DOACs) are now widely used in treatment of venous thromboembolism 
(VTE) and are recommended first-line over vitamin K antagonists (VKAs) in non-cancer associated 
VTE. Until recently, supportive measures and infusion of clotting factors were the only available 
options for reversal of DOACs. Within the last 4 years, approval of specific antidotes has led 
to hopes for improved outcomes in DOAC-related acute bleeding, however limitations remain 
including cost, availability and „real-world“ data. In severe and life-threatening bleeding events, 
use of non-specific (e.g. PCC) or specific (e.g. idarucizumab, andexanet alpha) reversal agents 
are recommended. However, further data is needed to compare outcomes between these two 
management strategies and identify the cost-effectiveness of these various strategies.
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Introduction
Bleeding is a common side effect 
of anticoagulant use. However, the 
majority of bleeding events are not 
life-threatening and can be managed 
conservatively.1 To assess the severity 
of an anticoagulant-related bleeding 
event, clinicians should identify the 
source (if possible) and location of 
bleeding, evaluate laboratory studies 
(including blood counts and coagula-
tion studies), and closely monitor vi-
tal signs. The first step in managing 
any significant bleeding event is to 
temporarily stop using the anticoag-
ulant. Local measures, such as man-
ual compression, can be useful in 
the case of skin-bleeds and epistaxis. 
Transfusion of blood products may be 
needed for more significant bleeding 
events. Ultimately, the decision to 
reverse an anticoagulant should be 
made based on the location of bleed-
ing, time since last use of the antico-
agulant, and patient‘s hemodynamic 
stability. The decision to reverse an 
anticoagulant is largely the same for 
patients with atrial fibrillation and 
venous thromboembolism. But the 
strategies for reversal differ based on 
the specific anticoagulant. The deci-
sion to restart the anticoagulant af-
ter bleeding has been controlled may 
differ based on indication.
Direct oral anticoagulants (DOACs) 
are now widely used in treatment 
of venous thromboembolism (VTE) 
and are recommended first-line over 
VKAs in non-cancer associated VTE2. 
While routine assessment of antico-
agulant effect is unnecessary, it can 
be helpful in determining the ap-
propriate management strategy for 
an acutely bleeding patient. Unlike 
VKAs, standard coagulation tests 
such as activated partial thrombo-
plastin time (aPTT) and prothrom-
bin time (PT)/INR are unreliable 
markers of anticoagulant effect in 
DOAC-treated patients. Time since 
last dose and end-organ function af-
fecting DOAC clearance should be 
used to guide the decision on need 
for reversal of the DOAC. Availabil-
ity of drug specific assays or use of 
a low-molecular weight heparin cal-
ibrated anti-Xa level can be useful 
to determine activity but should not 
delay treatment in those known to 
have DOAC on board.
The aim of this review was to de-
termine the appropriate manage-
ment strategy for an acutely bleed-
ing patient on DOACs. Comparing 
non-specific with specific reversal 
agents in severe and life-threaten-
ing bleeding, we want to determine 
outcomes between these two man-
agement strategies and identify the 
cost-effectiveness of these various 
strategies.
Material and methods
This review was conducted to pro-
vide an overview and update on di-
rect oral anticoagulants and their 
reversal agents. A literature search 
was conducted using PubMed, Med-
line, Cochrane Library, Medscape, 
UpToDate and  databases for orig-
inal studies, case reports, clinical 
guidelines, and clinical trial reports 
on DOACs and their reversal agents 
using relevant search terms and the 
combinations, including bleeding, 
DOACs and reversal agents. The ref-
erence list of review papers was also 
used to identify relevant publica-
tions. Inclusion was limited to pub-
lications available in English. The 
research period extended between 
2011-2019, and there were 20 studies 
that were selected as relevant refer-
ences.
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Results
Until recently, supportive measures 
and infusion of clotting factors were 
the only available options for rever-
sal of DOACs. Initial animal models 
evaluating activated PCC (aPCC) [FEI-
BA], 4-factor PCC, and recombinant 
factor VII demonstrated mixed and 
inconsistent effects on coagulation 
parameters, bleeding time, and he-
mostatic efficacy.3-7 Additionally, high 
dose 4F-PCC (50 units/kg) in healthy 
subjects reversed abnormal coag-
ulation tests from rivaroxaban but 
not dabigatran.8 The use of aPCC in 
dabigatran-associated acute bleed-
ing suggests good hemostatic efficacy 
as compared to historical controls9 
and specific antidote trials10. In apix-
aban and rivaroxaban patients, two 
observational cohort reports have 
described 4F-PCC use with hemosta-
sis rates of 70-80% and low rates of 
thromboembolism11-12 .
Within the last 4 years, approval of 
specific antidotes has led to hopes for 
improved outcomes in DOAC-related 
acute bleeding, however limitations 
remain including cost, availability 
(andexanet alfa), and „real-world“ 
data.
Table 1.  Specific Reversal Agents for Direct Oral Anticoagulants 20
Од 18 до 29 месеци Idarucizumab Andexanet Alpha Ciraparantag
Drug reversed Dabigatran
Rivaroxaban
Apixaban
Edoxaban (non-FDA)
LMWH (non-FDA)
Dabigatran
Xa inhibitors
LMWH
UFH
Mechanism
Monoclonal Ab binds 
Dabigatran with high 
affinity
Recombinant human 
factor Xa protein acts 
as a decoy
Noncovalent bonding 
and charge-charge 
interactions
Published Clinical 
Studies
Healthy volunteers; 
bleeding patients; 
emergent reversal
Healthy volunteers; 
bleeding patients;
Healthy volunteers
FDA approval Approved Approved Not approved
A majority of patients in both tri-
als demonstrated normalization of 
thrombin activity and reduction in 
unbound drug concentration. In RE-
VERSE-AD, unbound dabigatran lev-
els were suppressed for 12 hours at 
which point 23% of patients had re-
elevation of levels.13 In ANNEXA-4, 
unbound apixaban and rivaroxaban 
levels returned to that of the place-
bo group two hours after the end of 
the 2-hour infusion, however endog-
enous thrombin potential remained 
normalized.14 Hemostasis was report-
ed in a majority of patients in both 
trials. Use of agent specific antidotes 
is recommended over non-specific 
reversal agents for DOAC-associated 
life-threatening bleeding or bleeding 
at a critical site. If agent specific an-
tidotes are not available, based on ob-
servational data, aPCC (25-50 units/
АРХИВИ НА ЈАВНОТО ЗДРАВЈЕ
35
kg) is recommended for reversal of 
dabigatran and 4F-PCC (25-50 units/
kg) is recommended for reversal of 
oral anti-Xa inhibitors.1,2,14,15
Discussion
The acute management of anticoagu-
lant-related bleeding in patients with 
VTE should also include an assess-
ment for restarting anticoagulation 
once bleeding has been resolved. This 
is of particular importance for pa-
tients with VTE, who remain at ele-
vated risk for recurrence. In fact, the 
majority of thromboembolic events 
and deaths occurring in the AN-
NEXA-4 study occurred after bleed-
ing had been controlled but before 
anticoagulation had been resumed.14 
Among patients with atrial fibrilla-
tion who experienced an anticoagu-
lant-related bleeding, data suggests 
lower rates of ischemic stroke and 
death when the anticoagulant is re-
started.17 The same is likely to be true 
for patients with VTE. Recent guide-
lines recommend resuming anticoag-
ulation within 90 days if the patient 
is at moderate-high risk for VTE re-
currence and the risk of recurrent 
bleeding is adequately low.18,19
Conclusion
Bleeding is a common complication 
of chronic anticoagulant therapy. 
Most bleeding events can be managed 
conservatively, usually by omitting 
a few doses of the anticoagulant. In 
severe and life-threatening bleeding 
events, use of non-specific (e.g. PCC) 
or specific (e.g. idarucizumab, andex-
anet alpha) reversal agents are rec-
ommended. However, further data 
is needed to compare outcomes be-
tween these two management strat-
egies and identify the cost-effective-
ness of these various strategies. Once 
bleeding has been controlled, clini-
cians and patients should discuss the 
appropriateness of resuming antico-
agulant therapy to prevent potential-
ly life-threatening future thrombotic 
events.
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